Drug Combination Details
| General Information of the Combination (ID: C29997) | |||||
|---|---|---|---|---|---|
| Name | Wogonin NP Info | + | Tumor necrosis factor alpha Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Anaplastic large cell lymphoma
[ICD-11: 2A90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Activity | p105 | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Neutralization | TNFAlpha-induced free radical O2- | ||||
| In-vitro Model | ARAC-8C | CVCL_GZ09 | T acute lymphoblastic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Wogonin attenuates NF-kappaB activity by shifting TNFalpha-induced free radical .O(2)(-) to a more reduced nonradical product, H(2)O(2), and thereby sensitizes TNFalpha-resistant leukemia cells to TNFalpha-induced apoptosis. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Wogonin sensitizes resistant malignant cells to TNFalpha- and TRAIL-induced apoptosis. Blood. 2006 Dec 1;108(12):3700-6. | |||
